Does age matter? The impact of rodent age on study outcomes by Jackson, S.J. et al.
ab oratory
l i m i t e d
l
an imals
Original Article
Does age matter? The impact of rodent
age on study outcomes
Samuel J Jackson1,*, Nick Andrews2, Doug Ball3,
Ilaria Bellantuono4, James Gray3, Lamia Hachoumi5,
Alan Holmes6, Judy Latcham7, Anja Petrie8, Paul Potter9,
Andrew Rice10, Alison Ritchie11, Michelle Stewart12,
Carol Strepka13, Mark Yeoman5 and Kathryn Chapman1
Abstract
Rodent models produce data which underpin biomedical research and non-clinical drug trials, but translation
from rodents into successful clinical outcomes is often lacking. There is a growing body of evidence showing
that improving experimental design is key to improving the predictive nature of rodent studies and reducing
the number of animals used in research. Age, one important factor in experimental design, is often poorly
reported and can be overlooked. The authors conducted a survey to assess the age used for a range of
models, and the reasoning for age choice. From 297 respondents providing 611 responses, researchers
reported using rodents most often in the 6–20 week age range regardless of the biology being studied. The
age referred to as ‘adult’ by respondents varied between six and 20 weeks. Practical reasons for the choice of
rodent age were frequently given, with increased cost associated with using older animals and maintenance of
historical data comparability being two important limiting factors. These results highlight that choice of age is
inconsistent across the research community and often not based on the development or cellular ageing of the
system being studied. This could potentially result in decreased scientific validity and increased experimental
variability. In some cases the use of older animals may be beneficial. Increased scientific rigour in the choice
of the age of rodent may increase the translation of rodent models to humans.
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The most frequently used mammals in scientiﬁc
research are rodents, predominantly rats and mice.
There are various experimental factors which are
critical to the quality of data obtained from rodent
models and these factors diﬀer according to the
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requirements of the experiment.1 Previous studies have
shown that reporting of animal experiments in peer-
reviewed publications is poor due to omission of details
of experimental design such as blinding, randomiza-
tion, and details of strain, sex and age.2,3
Signiﬁcant diﬀerences exist in disease-relevant
systems in young or aged animals compared with
middle-aged counterparts, and these diﬀerences may
aﬀect the outcome of studies investigating basic disease
biology, mechanisms of drug action and eﬃcacy.
Inconsistent choice of age in rodent models between
experiments or laboratories has the potential to impact
on data quality, potentially increasing variability and
reducing relevance to the human disease being studied.
In basic or mechanistic studies, biological pathways or
mechanisms of action may be obscured by inter-animal
variability arising from inappropriately aged animals.
In drug development, the translation of compounds
from non-clinical research to phase II clinical trials has
been shown to be poor in many therapeutic areas, with a
lack of predictive rodent models for human disease
partly responsible for attrition.4,5 Use of a suboptimal
and variable age of animal could be contributing to this.
The age at which animal models are commonly used
is 8–12 weeks. In this age range, many developmental
processes are ongoing,6–11 and changes in physiology
with age may have a large impact on experimental vari-
ables. For example:
. Peak bone mass is not reached until around 26 weeks
of age in rodents.7,12,13
. The development of the immune system is deﬁned by
changes in thymus size and cellular content over
early development14,15 as well as key immunological
markers.16 It has been shown that B-cells have an
immature phenotype until four weeks of age,17 T-
cell responses mature around eight weeks of age,18
and T and B-lymphocyte production increases over
the ﬁrst 26 weeks of life.19
. Signiﬁcant brain growth is ongoing in the rat until
nine weeks of age6 and central nervous system mye-
lination in limbic structures is not complete until six
weeks of age,10 development of mouse spinal cord,
hippocampus and olfactory structures is ongoing
until 11 weeks of age.11
Additionally, older animals entering senescence
may respond diﬀerently to their younger counter-
parts.13,20–22 For example:
. Factors such as menopause and old age are risk fac-
tors for bone diseases in humans, but are poorly
modelled in younger rodents and require careful
consideration of translational biomarkers in older
rodents to ensure cross-species comparability.23–25
. The profound eﬀect of age in models of stroke has
been documented,26–28 and young animals have been
used to model a disease generally seen in older
humans. Alterations in blood ﬂow and brain bio-
chemistry with age have a signiﬁcant impact in
humans, but these pathologies are not reﬂected
when modelling the disease with young rodents.
Older rats have been shown to exhibit a diﬀerence
in susceptibility to,28 or take longer to recover
from,29 ischemic insults.
. Age-related phenotypes are being uncovered in com-
monly used inbred strains. For example, the widely
used C57BL/6J mouse has impaired glucose toler-
ance due to a missense mutation in nicotinamide
nucleotide transhydrogenase (Nnt),30 which has
implications for diabetic phenotypes, as well as caus-
ing age-related decline in mitochondrial func-
tions.31,32 In addition C57BL/6J mice have a
mutation in the cadherin 23 (Cdh23) gene, resulting
in age-related hearing loss.33 This may impact on
behavioural studies as the mice age.
. The microbiome plays important roles in the main-
tenance of appropriate immune system function and
response to disease. Ageing can aﬀect the composi-
tion of the mouse microbiome,34 and this has been
shown to modulate mouse models of allergic airway
disease,35 potentially reducing the quality of data
obtained.
. Drug metabolism by the liver has a critical impact
on systemically administered compounds, and is
therefore of primary importance during the devel-
opment of new pharmaceuticals. The gene expres-
sion of critical liver enzymes is dramatically
diﬀerent between young and older counter-
parts,36,37 potentially leading to discrepancies or
errors aﬀecting drug candidate selection or
development.
A working group was convened by the National
Centre for the Replacement, Reﬁnement and
Reduction of Animals in Research (NC3Rs) to explore
the age of rodents used to model physiology, disease or
drug eﬃcacy, and to assess the impact on scientiﬁc out-
comes, with the aim of improving selection of the age of
rodent models. Here, we present literature examples
illustrating the importance of a well-informed age
choice, and data from a survey regarding the age of
rodents used in biomedical research. In addition, two
data-based case studies are included as supplemental
data (Figures S2 and S3; all supplemental material
can be found online at http://lan.sagepub.com). By
improving decision-making around the age of rodent
used in biomedical research, the number of animals
used can be reduced while maintaining or improving
data quality.
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Methods
Survey regarding age of rodent used
A cross-sector working group, reﬂected in the author-
ship, was formed from a diverse range of disciplines
with an interest in the impact of age on rodent
models of disease. In order to explore the age at
which rodents are currently being used in research, an
online survey was formulated by the expert working
group with reference to published guidance on survey
design.38 The survey requested data on the type of
rodent model used by the researcher, and the age
chosen for the model (see supplemental Table S1).
Researchers could enter information on up to ﬁve sepa-
rate models. Researchers were also asked for additional
information on why the speciﬁc age was chosen and
evidence for age suitability of the model. A drop-
down list was used to establish reasons for choice of
age (see supplemental Table S1 Q4).
The survey was pilot-tested and reﬁned within the
working group, and distributed as a hyperlink in a
standard text via 20 learned societies and research cha-
rities, as well as individual scientists and scientiﬁc net-
works. The disciplines covered cancer, cardiovascular
disease, endocrinology, immunology, musculoskeletal
disease, neuroscience, and respiratory disease, and
encompassed academic and pharmaceutical researchers
in the UK and EU. This enabled distribution to a repre-
sentative sample of researchers, as described in the
Results section.
The data analysis workﬂow is shown in supplemen-
tal Figure S1. Data from the survey was anonymized
and initially analysed to assess information about
respondent location and ﬁeld of work, and which
models were represented in the data-set. Models
which could not be classiﬁed (see below) or without a
justiﬁcation for the age used were removed. Each model
was individually classiﬁed by ‘System/Process’ (see sup-
plemental Table S2) and ‘Disease/Condition’ (a list of
233 diseases and conditions) as deﬁned by the
Wellcome Trust (London, UK).39
Comparison of age used for the same model para-
digm across laboratories. Where the same model
paradigm was reported in multiple responses, these
were grouped and the range of ages plotted.
Age considered ‘adult’. Where the choice of age was
justiﬁed by describing the animal as ‘adult’, the range of
ages was plotted as a frequency graph.
Results
Given the literature demonstrations of changes in dis-
ease modelling in rodents with age, a survey was
designed to collect information on the age at which
researchers used rodents to model human disease or
physiology. A diagrammatic description of the data
workﬂow followed in this publication can be found in
supplemental Figure S1.
There were 297 respondents to the survey, predomi-
nantly from the academic sector (80%), with 18% from
the pharmaceutical sector. Location information was
provided by 108 respondents (35% of the total) which
demonstrated that responses were received from 27 UK
and 31 non-UK locations.
The survey allowed for up to four responses per
respondent. The total number of responses received
was 611, representing a cross section of disciplines
including neuroscience, immunology, cancer, genetics,
physiology and toxicology. The range of ages
reported was wide (2–160 weeks) but was heavily clus-
tered around the 8–12 week age range for both mice
and rats.
When the same model paradigm was reported multi-
ple times, comparison of the age used across diﬀerent
laboratories was possible. Figure 1 illustrates the range
of ages used for each model. This demonstrates that
researchers in diﬀerent laboratories used diﬀerent ages
of animal in the same experimental paradigm.
Responses (11.5%) cited that the reason for the
choice of age was the rodent being ‘adult’. However,
the age range over which the term ‘adult’ was applied
across these responses was 6–20 weeks (Figure 2). This
illustrates the potential discrepancy when using general
descriptions of rodent age.
Ten percent of the total responses described the use
of rodents over 16 weeks of age (24% of these in rats
and 76% in mice). The age in these cases was justiﬁed
by one of four reasons: onset of the disease in rodent
did not occur until more than 16 weeks had passed
(39%); the researchers wanted to capture advanced dis-
ease time-points including comorbidities which
occurred after 16 weeks (33%); the animal was of a
suﬃcient size for surgery to be performed (10%); the
model was of a disease of older age in humans (18%).
A drop-down list was used to capture the reasons
behind the choice of age. Respondents supplied 704
responses, with the highest cited reasons for the
choice of age being historical data comparability
(24%), supply/availability (18%) and cost (15%).
When these reasons were split between academic and
industry respondents, a diﬀerence was evident
(Figure 3). Academic respondents cited the cost of ani-
mals as the factor which impacted their choice of
rodent age the most (18% academic versus 6% indus-
try), while industry respondents reported that historical
data comparability was the most inﬂuential factor on
the choice of rodent age (28% industry versus 23%
academic).
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Figure 1. Age ranges of rodent reported for specific models. Where a model was described sufficiently, there was
opportunity to compare the age of specific model systems across responses. Respondents described that a range of ages
of rodent were used for a given model. Ages used for all models clustered around the 8–12 week range, regardless of the
biology being studied. The use of some ages, particularly at the low or high extremes, was justified by a specific biological
reasoning.
Figure 2. Age considered adult: models described as ‘adult’ were identified, and the ages plotted as frequencies. This
illustrates that the description ‘adult’ can encompass a wide range of ages, between six and 20 weeks for mice and
between eight and 16 weeks for rats. These ages encompass ongoing development in a range of systems which could
adversely affect the outcomes of an experiment. This could be avoided by basing the choice of age on the development of
the system under examination. In addition, precise ages should be reported rather than ambiguous terminology such as
‘adult’.
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Discussion
Taken together, these data demonstrate that: (1) choos-
ing an age of rodent relevant to the human disease
being studied can have a critical impact on the perfor-
mance of the model; (2) the age of rodent is often based
on practical considerations or convention; and (3) the
age of rodent reported as ‘adult’ is inconsistent between
studies or laboratories.
Reporting
Given that reporting of animal age and the reasoning
behind the choice of age in publications has generally
been poor,1 age choices are often based on convention
or anecdotal evidence. The NC3Rs’ ARRIVE guide-
lines2 set out the attributes of experimental design to
be reported to increase the reproducibility and trans-
parency of in vivo experiments, including the age of
animal used. More widespread and stringent adoption
of the ARRIVE guidelines will ensure that reporting of
animal age is more consistent in the future.
Consistency in age choice
The majority of responses described using animals
between eight and 12 weeks, with a range from two
to 120 weeks of age. When the same model paradigm
was described in multiple responses, these were com-
pared; the age used varied over a range of up to 20
weeks. This discrepancy in the age of animal used
between diﬀerent laboratories using the same model
could lead to data variability obtained between those
laboratories. When rodent age is not accurately
reported, it cannot be taken into account in subsequent
experiments, and this may lead to results not being
repeatable elsewhere. This illustrates the importance
of using standardized or consensus protocols,
Figure 3. Factors influencing the choice of age of rodent in responses from academic versus industry-based scientists.
Respondents were asked to choose reason(s) for their choice of age from a drop-down list. Academic respondents were
more concerned with the cost of the animals (18% academic versus 6% industry), whereas industry respondents were
slightly more concerned with historical data comparability (23% academic versus 28% industry). This illustrates that
‘practical’ factors can affect age choices, and these differ in academia and industry.
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and designing experiments with reference to published
work on the biology of the system being studied.
Age considered ‘adult’
By examining responses which indicated that the age
used represented an ‘adult’, the disparity when using
this terminology was uncovered. The deﬁnition of
‘adult’ in this context is likely to be related to the
sexual maturity of the rodent. Indeed, rodents are sexu-
ally mature and able to breed from around ﬁve weeks of
age.40–42 However, this is not a suﬃcient basis on which
to consider the whole animal to be fully developed.
Many systems are immature at this age and may take
weeks or months to develop to maturity. Additionally,
there may be diﬀerences in the maturity of diﬀerent
strains at a particular age.43,44 The maturity of the
system can signiﬁcantly impact the outcome of an
experiment, as demonstrated in the literature examples
cited in this manuscript. ‘Adult’ would be deﬁned dif-
ferently in many of these examples; therefore this or
other terminology referring to a ‘stage of life’ should
be replaced with the actual age used when designing,
documenting and reporting an experiment.
Where animals over 16 weeks of age were detailed in
the response, the range of reasons used to justify this
were very narrow, either pertaining to the biology of
the model animal or the human disease being modelled.
This reﬂects the fact that older animals are only likely
to be used when justiﬁed by a speciﬁc biological attri-
bute related to ageing; this principle is rarely applied to
younger rodents.
Reasons for age choice
By gathering qualitative data regarding reasons for age
choice for a large range of rodent models, we have
demonstrated that ‘cost’ and ‘supply’ are second only
to ‘historical data compatibility’ as reasons for choos-
ing the age of rodent for a study. The cost pressure is
particularly evident when academic respondents are
analysed separately from pharmaceutical company
respondents. Several academic respondents commented
that cost precluded modelling in aged animals and that
including higher costs for aged animals would appear
unattractive on a grant application. Comparison of the
cost of animals at six and 12 weeks from one major
commercial supplier to the UK and US markets illus-
trates this issue: purchase of animals at 12 weeks will
result in a cost increase of at least 50% per animal,
sometimes close to 100% (Table 1). Researchers who
purchase young animals and age them in-house will
also face increased costs for housing and husbandry
during this period. In order to support more robust
and predictive rodent studies, funding bodies and
researchers will need to work together to develop a
strategy which takes into account that use of older
rodents may be beneﬁcial to data quality and the
appropriate use of animals, and where justiﬁed assess
the increased animal costs on grant applications
accordingly.
Comparisons between mice and humans
Some respondents to the survey indicated that they
were using a certain age of rodent as it was an equiva-
lent age to the human being modelled. Equivalent ages
between rodent and human have been deﬁned by com-
paring survival rates between mice and humans over
their lifespans. For example, one study41 deﬁned a
mature adult C57BL6/J mouse as 3–6 months (equiva-
lent in this analysis to 20–30 human years), a middle-
aged mouse as 10–14 months (equivalent to 38–47
human years) and an old mouse as 18–24 months
(equivalent to 56–69 human years). The mature adult
mouse represents a stage where development has
ceased, but senescence has not yet started, and is
recommended as the comparative age for studies into
the eﬀects of ageing. Using this approach, 12 weeks
should be the minimum for a model of adult disease.
Similarly calculations to ascertain equivalent rat and
human ages have been published which illustrate the
discrepancy in the speed of development at diﬀerent
stages between rats and humans.40,42 A framework
and online tool have also been developed to translate
neurobiological development across multiple species,
including rodents and humans.45,46
Databases and information sharing
The Mouse Phenome Database47,48 (Jackson
Laboratory, Bar Harbor, ME, USA) was the most fre-
quently cited resource in the questionnaire for assessing
the appropriate age for mice. Other resources cited
include the Age-Phenome Knowledgebase49 (Ben
Gurion University of the Negev, Beer Sheva, Israel)
which allows access to literature sources based on
searches of age, phenotype, or both, in mice and
humans. Similar resources for rats are not available,
but the Rat Genome Database (Bioinformatics
Table 1. Percentage increase in cost of 12-week-old
rodents compared with 6-week-old rodents.
C57BL/6J BALB/c SD Wistar
Commercial UK supplier 57 91 69 98
Commercial US supplier 82 68 95 76
Source: a commercial laboratory animal supplier (correct as of
August 2015). SD: Sprague-Dawley.
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Research Center, Milwaukee, WI, USA) is intended to
encompass these data in the future.50
To facilitate studies on aged rodents and reduce the
overall numbers of animals used, networks such as the
Shared Ageing Research Models (ShARM) initiative51
aim to promote the use and knowledge of aged rodents
as models of ageing. In the US, the Aging Rodent
Colonies project at the National Institute on Aging
(Bethesda, MD, USA) banks and breeds aged rodents
and tissues for supply to National Institutes of Health
(NIH)-funded researchers working on ageing.52
Conclusion and recommendations for
best practice
Use of an inconsistent age of rodents in many areas of
scientiﬁc research may impact data quality. By increas-
ing awareness of this basic experimental parameter, it
may be possible to improve model reliability and reduce
the number of animals used in some experiments. Use
of an appropriate and consistent age choice plus an
improvement in reporting of age will require engage-
ment of researchers across the academic and industry
communities. Importantly, given the cost implications
of using older animals, engagement of funding bodies is
required to ensure that this is taken into account in
research funding applications.
Recommendations
. The age of rodent used in a study should be based on
the development or cellular ageing of the system or
disease under scrutiny.
. Funding bodies and grant reviewers may need to
take into account the increased costs associated
with using older animals, and application for
increased funding for this should be considered
where justiﬁed.
. Eﬀective communication between researchers and
animal facility staﬀ/veterinarians will increase the
likelihood that an appropriate age is chosen.
. Accurate and consistent reporting of age in
peer-reviewed literature will allow comparison of
experimental methodology and development of con-
sensus-based best practice.
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